论文部分内容阅读
目的探讨血清黄嘌呤氧化酶活性在代谢综合征患者中的意义。方法测定89例代谢综合征患者和80例健康对照者血清黄嘌呤氧化酶活性及血清尿酸水平等临床生化指标。结果代谢综合征患组黄嘌呤氧化酶活性显著高于健康对照组[(33.2±8.71)U/L vs(4.2±0.96)U/L](P<0.001);合并脂肪肝的代谢综合征组血清黄嘌呤氧化酶活性显著高于无脂肪肝组[(41.2±8.93)U/L vs(19.1±6.31)U/L](P<0.001);代谢综合征组血清黄嘌呤氧化酶活性与血清尿酸水平(r=0.773,P<0.01)及总胆固醇(r=0.603,P=0.021)存在明显正相关性,而与高密度脂蛋白胆固醇水平存在一定的负相关性(r=-0.551,P=0.029)。结论黄嘌呤氧化酶通过多种分子机制密切介入代谢综合征的发生发展过程。
Objective To investigate the significance of serum xanthine oxidase activity in patients with metabolic syndrome. Methods Serum xanthine oxidase activity and serum uric acid levels were measured in 89 patients with metabolic syndrome and 80 healthy controls. Results The xanthine oxidase activity in patients with metabolic syndrome was significantly higher than that in healthy controls [(33.2 ± 8.71) U / L vs (4.2 ± 0.96) U / L] (P <0.001) The serum xanthine oxidase activity was significantly higher than that of the non-fatty liver group (41.2 ± 8.93 U / L vs 19.1 ± 6.31 U / L, P <0.001). The serum xanthine oxidase activity There was a significant positive correlation between uric acid level (r = 0.773, P <0.01) and total cholesterol (r = 0.603, P = 0.021), but negatively correlated with high density lipoprotein cholesterol (r = -0.551, P = 0.029). Conclusion Xanthine oxidase participates closely in the development of metabolic syndrome through a variety of molecular mechanisms.